Lazard Asset Management LLC raised its position in Vericel Co. (NASDAQ:VCEL – Get Rating) by 106.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 3,465 shares of the biotechnology company’s stock after purchasing an additional 1,785 shares during the quarter. Lazard Asset Management LLC’s holdings in Vericel were worth $87,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in shares of Vericel during the second quarter valued at approximately $110,000. Engineers Gate Manager LP bought a new position in Vericel in the 1st quarter valued at $222,000. US Bancorp DE increased its stake in shares of Vericel by 600.3% in the 1st quarter. US Bancorp DE now owns 6,184 shares of the biotechnology company’s stock valued at $236,000 after buying an additional 5,301 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of Vericel during the first quarter worth $240,000. Finally, Baird Financial Group Inc. acquired a new position in shares of Vericel during the first quarter valued at $240,000.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on VCEL. Stephens initiated coverage on Vericel in a research report on Thursday, October 13th. They issued an “overweight” rating and a $40.00 price objective for the company. StockNews.com began coverage on shares of Vericel in a research note on Wednesday, October 12th. They set a “sell” rating for the company. BTIG Research lowered shares of Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, November 9th. HC Wainwright reduced their price objective on shares of Vericel from $53.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, November 10th. Finally, Truist Financial cut shares of Vericel to a “hold” rating in a research note on Tuesday, November 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.40.
Vericel Stock Performance
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.